Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2012

View Archived Issues

AEterna Zentaris presents promising in vivo data for AEZS-136

SQ-609: a dipiperidine for tuberculosis

SNS01-T combined with bortezomib effective in mouse tumor model

New bimatoprost prodrugs prepared at Allergan

Santaris Pharma discloses new oligonucleotides

Last patient completes treatment in phase IIb bremelanotide trial

AB-103 receives fast track designation from FDA

U.S. team presents novel chimeric antibodies for poliovirus infection

Zalicus reports topline phase IIb results for Synavive in rheumatoid arthritis

Pro Bono Bio obtains exclusive license to TheraPEG technology

Transgene Biotek patents novel fusion proteins for HIV

Sanofi presents novel PI3K-beta inhibitor with activity in PTEN-deficient tumors

Bristol-Myers licenses Summit's Seglin drug discovery platform

Novel antirheumatic drug iguratimod launched in Japan

Radiolabeled TSPO shows potential as a new imaging biomarker of NAFLD

Patient dosing begins in phase I/II trial of Pergamum's therapeutic peptide for hard-to-heal wounds

First launch of Pixuvri carried out in European countries

Arsanis receives additional grants for anti-infective monoclonal antibody programs

Eaton Scientific to develop non-hormonal transdermal patch for hot flashes

FDA cites manufacturing deficiencies in Navidea's Lymphoseek NDA

MedImmune and WuXi AppTec to develop novel biologic for Chinese market

Critical Outcome Technologies takes steps toward IND filing of oral formulation

Researchers from Peregrine present topline results from a phase II study in NSCLC

Japanese MHLW grants priority review to Bayer's regorafenib NDA for colorectal cancer